MeSH term
Frequency | Condition_Probility | Albumins/metabolism | 2 | 1.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 2 | 2.0 |
Humans | 281 | 0.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Indoles/*therapeutic use | 2 | 1.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Aged | 41 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Female | 95 | 0.0 |
Animals | 65 | 0.0 |
DNA Repair | 2 | 0.0 |
Gene Expression | 7 | 0.0 |
African Continental Ancestry Group | 4 | 1.0 |
Alleles | 22 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 12 | 11.0 |
Base Sequence | 17 | 0.0 |
DNA/genetics | 3 | 0.0 |
Gene Deletion | 5 | 0.0 |
Japan | 13 | 0.0 |
Mixed Function Oxygenases/*genetics | 34 | 24.0 |
Models, Genetic | 3 | 0.0 |
Molecular Sequence Data | 19 | 0.0 |
Phenotype | 20 | 0.0 |
Research Support, Non-U.S. Gov't | 162 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
*Aryl Hydrocarbon Hydroxylases | 102 | 12.0 |
Cytochrome P-450 CYP2E1/*genetics | 4 | 3.0 |
Cytochrome P-450 Enzyme System/*genetics | 27 | 6.0 |
Male | 113 | 0.0 |
Polymorphism, Genetic | 15 | 0.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 18 | 13.0 |
Enzyme Inhibitors/pharmacology | 20 | 0.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 10 | 14.0 |
Kinetics | 50 | 0.0 |
Microsomes, Liver/drug effects/*enzymology | 6 | 13.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 7 | 15.0 |
Transfection | 17 | 0.0 |
Comparative Study | 54 | 0.0 |
Cytochrome P-450 CYP1A2/metabolism | 8 | 8.0 |
Cytochrome P-450 CYP2E1/metabolism | 5 | 11.0 |
Cytochrome P-450 Enzyme System/*metabolism | 32 | 6.0 |
Isoenzymes/metabolism | 9 | 1.0 |
Rats | 31 | 0.0 |
Recombinant Proteins/metabolism | 15 | 0.0 |
Administration, Oral | 7 | 0.0 |
Area Under Curve | 4 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/metabolism | 2 | 5.0 |
Coumarins/metabolism | 8 | 32.0 |
DNA Primers/chemistry | 3 | 0.0 |
Escherichia coli | 3 | 0.0 |
Genotype | 30 | 0.0 |
Middle Aged | 68 | 0.0 |
Mixed Function Oxygenases/*genetics/metabolism | 6 | 14.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Polymerase Chain Reaction | 13 | 0.0 |
Enzyme Inhibitors/*pharmacology | 16 | 2.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Adult | 75 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Biological Markers/urine | 2 | 3.0 |
Liver/drug effects/enzymology | 2 | 3.0 |
Catalysis | 13 | 1.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 12 | 10.0 |
In Vitro | 31 | 0.0 |
Isoenzymes/antagonists & inhibitors | 2 | 4.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 3 | 10.0 |
Substrate Specificity | 20 | 0.0 |
Chromatography, High Pressure Liquid | 19 | 1.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 10 | 14.0 |
Microsomes, Liver/drug effects/enzymology | 12 | 12.0 |
*Steroid 16-alpha-Hydroxylase | 6 | 3.0 |
Steroid Hydroxylases/*antagonists & inhibitors/metabolism | 2 | 22.0 |
Blotting, Northern | 3 | 0.0 |
Blotting, Western | 13 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Cells, Cultured | 14 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics | 2 | 5.0 |
Dose-Response Relationship, Drug | 17 | 0.0 |
Hepatocytes/*drug effects/enzymology | 2 | 14.0 |
Protein Isoforms | 2 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Enzyme Inhibitors/*chemistry/*pharmacology | 2 | 13.0 |
Quantitative Structure-Activity Relationship | 2 | 6.0 |
Models, Molecular | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/*metabolism | 2 | 25.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
Microsomes, Liver/*enzymology | 21 | 10.0 |
Drug Interactions | 14 | 1.0 |
Enzyme Inhibitors/administration & dosage/*pharmacology | 2 | 12.0 |
Inhibitory Concentration 50 | 4 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 56 | 0.0 |
*Gene Deletion | 8 | 0.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Homozygote | 5 | 0.0 |
*Mutation | 5 | 0.0 |
Odds Ratio | 5 | 0.0 |
Risk Factors | 14 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics/*metabolism | 7 | 14.0 |
Gene Frequency/genetics | 3 | 0.0 |
Mixed Function Oxygenases/*genetics/*metabolism | 7 | 38.0 |
Mutation | 5 | 0.0 |
Polymorphism, Genetic/*genetics | 10 | 0.0 |
Prevalence | 3 | 0.0 |
Sex Factors | 5 | 0.0 |
Smoking/genetics/metabolism | 2 | 33.0 |
Umbelliferones/urine | 6 | 85.0 |
Variation (Genetics) | 4 | 0.0 |
Caffeine/*metabolism | 3 | 11.0 |
Case-Control Studies | 11 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 2 | 2.0 |
Microsomes, Liver/metabolism | 11 | 6.0 |
Oxidation-Reduction | 18 | 1.0 |
*Polymorphism, Genetic | 19 | 0.0 |
Smoking/*genetics | 6 | 14.0 |
Smoking Cessation | 2 | 11.0 |
Tobacco Use Disorder/*genetics | 2 | 28.0 |
Biological Markers | 2 | 0.0 |
NADP/metabolism | 4 | 3.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors | 3 | 6.0 |
Ditiocarb/pharmacology | 2 | 11.0 |
Pyrazoles/pharmacology | 3 | 6.0 |
Autoantibodies/*blood | 3 | 1.0 |
Mutagenicity Tests/*methods | 5 | 19.0 |
Nitrosamines/*toxicity | 2 | 20.0 |
Recombinant Proteins/drug effects/genetics/metabolism | 2 | 12.0 |
Tobacco | 2 | 7.0 |
Neoplasms/chemically induced | 2 | 16.0 |
Gene Expression Regulation, Enzymologic | 5 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Hydroxylation/drug effects | 2 | 5.0 |
Microsomes, Liver/*drug effects/enzymology | 4 | 11.0 |
Time Factors | 8 | 0.0 |
Micronucleus Tests | 3 | 6.0 |
Microsomes, Liver/enzymology | 9 | 4.0 |
Cloning, Molecular | 7 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
Exons/genetics | 3 | 0.0 |
*Gene Frequency | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 5 | 0.0 |
Cotinine/metabolism | 2 | 33.0 |
Nicotine/metabolism | 3 | 75.0 |
Smoking/adverse effects | 2 | 0.0 |
Mixed Function Oxygenases/*metabolism | 15 | 10.0 |
Oxidoreductases, N-Demethylating/*metabolism | 3 | 3.0 |
Saccharomyces cerevisiae/enzymology | 2 | 3.0 |
Cytochrome P-450 CYP2D6/metabolism | 4 | 10.0 |
Mixed Function Oxygenases/metabolism | 12 | 8.0 |
Biotransformation | 22 | 4.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 2 | 6.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 18 | 12.0 |
Genetic Engineering | 4 | 4.0 |
Mixed Function Oxygenases/genetics/metabolism | 3 | 13.0 |
Mutagenicity Tests | 5 | 3.0 |
NADPH-Ferrihemoprotein Reductase/genetics/metabolism | 2 | 28.0 |
Recombinant Proteins/genetics/metabolism | 4 | 0.0 |
Salmonella typhimurium/drug effects/genetics | 2 | 14.0 |
Liver/*enzymology | 4 | 0.0 |
Microsomes, Liver/enzymology/*metabolism | 7 | 9.0 |
Spectrophotometry, Ultraviolet | 3 | 1.0 |
Adolescent | 15 | 0.0 |
Child | 9 | 0.0 |
Child, Preschool | 6 | 0.0 |
3' Untranslated Regions/*metabolism | 2 | 50.0 |
Microsomes, Liver/*metabolism | 13 | 7.0 |
Mixed Function Oxygenases/genetics/*metabolism | 3 | 6.0 |
Molecular Weight | 2 | 0.0 |
Hepatocytes/drug effects/*enzymology | 2 | 18.0 |
Macaca fascicularis | 4 | 1.0 |
Autoantigens/*immunology | 2 | 1.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*immunology | 2 | 28.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Mixed Function Oxygenases/*immunology | 2 | 100.0 |
Lipid Peroxidation/*drug effects | 2 | 6.0 |
Malondialdehyde/metabolism | 2 | 7.0 |
Microsomes, Liver/drug effects/enzymology/*metabolism | 3 | 16.0 |
Baculoviridae | 2 | 3.0 |
Gene Expression Regulation | 2 | 0.0 |
Insects | 2 | 1.0 |
Isoenzymes | 2 | 1.0 |
Liver/drug effects/*enzymology | 2 | 5.0 |
Mice | 22 | 0.0 |
Microsomes, Liver | 2 | 20.0 |
Rats, Sprague-Dawley | 8 | 0.0 |
Enzyme Induction | 5 | 0.0 |
Epoxy Compounds/metabolism | 2 | 25.0 |
Mixed Function Oxygenases/physiology | 2 | 16.0 |
Oxidoreductases, N-Demethylating/physiology | 2 | 33.0 |
Species Specificity | 12 | 0.0 |
Carcinogens/*metabolism | 4 | 5.0 |
Cytochrome P-450 Enzyme System/*physiology | 9 | 15.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Cattle | 3 | 0.0 |
Cytochrome P-450 Enzyme System/metabolism | 6 | 2.0 |
Microsomes/metabolism | 5 | 4.0 |
Pharmaceutical Preparations/metabolism | 3 | 9.0 |
Rats, Wistar | 6 | 0.0 |
*Genetics, Population | 3 | 0.0 |
Cytochrome P-450 CYP1A1/metabolism | 4 | 6.0 |
Enzyme Activation | 3 | 0.0 |
NADPH-Ferrihemoprotein Reductase/metabolism | 3 | 13.0 |
Protein Binding | 4 | 0.0 |
Liver/metabolism | 5 | 0.0 |
Microsomes, Liver/enzymology/metabolism | 3 | 4.0 |
Models, Chemical | 2 | 0.0 |
Binding, Competitive/drug effects | 2 | 3.0 |
Gene Frequency | 10 | 0.0 |
Heterozygote | 4 | 0.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/metabolism | 7 | 22.0 |
Biological Markers/analysis | 3 | 0.0 |
Reference Values | 5 | 0.0 |
*Smoking | 3 | 3.0 |
Asian Continental Ancestry Group/genetics | 3 | 0.0 |
Cell Line | 19 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Gene Expression/physiology | 2 | 0.0 |
Nucleic Acid Hybridization/methods | 3 | 4.0 |
Epithelial Cells/enzymology | 2 | 5.0 |
Isoenzymes/antagonists & inhibitors/genetics/*metabolism | 2 | 14.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
*Gene Expression | 4 | 0.0 |
Hydroxylation | 18 | 5.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Methoxsalen/*pharmacology | 3 | 37.0 |
Mixed Function Oxygenases/*antagonists & inhibitors | 8 | 19.0 |
Smoking/*adverse effects | 3 | 1.0 |
*Alleles | 5 | 0.0 |
Genetic Predisposition to Disease | 6 | 0.0 |
*Genotype | 2 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Amino Acid Sequence | 10 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Point Mutation | 2 | 0.0 |
Cytochrome P-450 CYP1A2/*metabolism | 2 | 2.0 |
Liver Function Tests | 4 | 2.0 |
Mixed Function Oxygenases/antagonists & inhibitors/genetics/*metabolism | 2 | 22.0 |
Nicotine/*metabolism | 11 | 100.0 |
China | 4 | 0.0 |
Esophageal Neoplasms/*genetics | 2 | 2.0 |
Lung Neoplasms/*genetics | 3 | 1.0 |
Isoenzymes/genetics | 2 | 0.0 |
Smoking/genetics | 2 | 10.0 |
Anticoagulants/*metabolism | 4 | 12.0 |
Coumarins/*metabolism | 9 | 60.0 |
Ganglionic Stimulants/*metabolism | 2 | 100.0 |
Binding Sites | 3 | 0.0 |
Methoxsalen/pharmacology | 4 | 50.0 |
Molecular Structure | 2 | 0.0 |
*Monoterpenes | 2 | 20.0 |
Spectrophotometry | 2 | 1.0 |
Acetonitriles/pharmacology | 2 | 50.0 |
Dimethyl Sulfoxide/pharmacology | 2 | 2.0 |
Ethanol/pharmacology | 2 | 3.0 |
Hepatocytes/*drug effects/*enzymology | 2 | 28.0 |
Methanol/pharmacology | 2 | 18.0 |
Solvents/*pharmacology | 3 | 30.0 |
Tissue Distribution | 2 | 0.0 |
Antimetabolites, Antineoplastic/*metabolism | 2 | 33.0 |
Fluorouracil/*metabolism | 2 | 50.0 |
Mixed Function Oxygenases/*physiology | 6 | 19.0 |
Tegafur/*metabolism | 2 | 66.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 9 | 7.0 |
Mutagens/*toxicity | 4 | 3.0 |
Plasmids | 2 | 0.0 |
Salmonella typhimurium/*genetics | 2 | 28.0 |
NADPH-Ferrihemoprotein Reductase/*genetics | 2 | 40.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Sensitivity and Specificity | 8 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Sulfaphenazole/pharmacology | 3 | 10.0 |
Cross-Over Studies | 4 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Smoking/*metabolism | 2 | 4.0 |
Biotransformation/drug effects | 2 | 6.0 |
Enzyme Induction/drug effects | 4 | 1.0 |
Phenobarbital/pharmacology | 2 | 3.0 |
Cytochrome P-450 Enzyme System/genetics | 3 | 2.0 |
Mixed Function Oxygenases/genetics | 3 | 7.0 |
5' Flanking Region/genetics | 3 | 3.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
Metabolic Clearance Rate | 3 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
NADPH-Ferrihemoprotein Reductase | 2 | 15.0 |
Troleandomycin/pharmacology | 3 | 5.0 |
Microsomes/enzymology | 6 | 5.0 |
Liver/enzymology | 5 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Immunization | 2 | 0.0 |
Isoenzymes/*metabolism | 6 | 2.0 |
Mice, Inbred DBA | 6 | 1.0 |
Exons | 4 | 0.0 |
Introns | 2 | 0.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Isoenzymes/*antagonists & inhibitors | 2 | 6.0 |
Canada | 2 | 1.0 |
Indians, North American/*genetics | 2 | 2.0 |
Antimalarials/*metabolism | 2 | 25.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Ketoconazole/pharmacology | 4 | 4.0 |
Orphenadrine/pharmacology | 2 | 50.0 |
Regression Analysis | 2 | 0.0 |
Sesquiterpenes/*metabolism | 2 | 50.0 |
Aryl Hydrocarbon Hydroxylases/*antagonists & inhibitors | 3 | 18.0 |
Drug Evaluation, Preclinical/methods | 2 | 6.0 |
Cytochrome P-450 Enzyme System/*analysis/metabolism | 2 | 66.0 |
Escherichia coli/genetics | 4 | 0.0 |
Mixed Function Oxygenases/*analysis/metabolism | 2 | 100.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Isoenzymes/genetics/*metabolism | 5 | 5.0 |
Blotting, Southern | 3 | 0.0 |
Spain | 2 | 0.0 |
Steroid Hydroxylases/*genetics | 3 | 3.0 |
Cross Reactions | 3 | 0.0 |
Dogs | 2 | 0.0 |
Haplorhini | 2 | 0.0 |
Pharmaceutical Preparations/*metabolism | 4 | 4.0 |
Spodoptera/virology | 2 | 25.0 |
Testosterone/metabolism | 5 | 3.0 |
Cytochrome P-450 CYP2E1/genetics | 2 | 5.0 |
Neoplasms/*enzymology/*genetics | 2 | 16.0 |
DNA Primers | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Genetic Screening/*methods | 2 | 1.0 |
Gene Library | 2 | 0.0 |
*Multigene Family | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Antibodies, Blocking/pharmacology | 3 | 3.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 2 | 7.0 |
Cell Survival/drug effects/physiology | 2 | 2.0 |
Rabbits | 10 | 0.0 |
DNA Probes | 2 | 0.0 |
B-Lymphocytes/enzymology | 2 | 5.0 |
Anisoles/*metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/immunology/*metabolism | 5 | 33.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Mixed Function Oxygenases/immunology/*metabolism | 3 | 50.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 4 | 8.0 |
English Abstract | 6 | 0.0 |
Oxidoreductases, N-Demethylating/*physiology | 3 | 30.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 6 | 8.0 |
Pyridines/*metabolism | 2 | 20.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Oxidoreductases/*genetics/metabolism | 2 | 10.0 |
Arylamine N-Acetyltransferase/genetics | 2 | 3.0 |
Cohort Studies | 2 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
Xenobiotics/*metabolism | 4 | 7.0 |
Disulfiram/*pharmacokinetics | 2 | 100.0 |
Cytochrome P-450 CYP2D6/*genetics | 2 | 3.0 |
Immunoblotting | 7 | 0.0 |
Dealkylation | 3 | 5.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Isoenzymes/genetics/metabolism | 4 | 2.0 |
DNA, Complementary | 4 | 0.0 |
Hypnotics and Sedatives/*metabolism | 2 | 28.0 |
Age Factors | 2 | 0.0 |
Antifungal Agents/pharmacology | 2 | 5.0 |
Asian Continental Ancestry Group/*genetics | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Umbelliferones/metabolism | 3 | 50.0 |
Immunohistochemistry | 3 | 0.0 |
Pedigree | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Coumarins/pharmacology | 2 | 10.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 3 | 8.0 |
Methylation | 2 | 0.0 |
Quinidine/pharmacology | 2 | 4.0 |
Liver/*drug effects/metabolism | 2 | 4.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
Genetic Vectors | 4 | 0.0 |
Antibody Specificity | 4 | 0.0 |
Immune Sera/immunology | 2 | 1.0 |
Antibodies/immunology | 2 | 0.0 |
Enzyme Inhibitors/chemistry/*pharmacology | 2 | 6.0 |
Mixed Function Oxygenases/biosynthesis/*genetics/*metabolism | 2 | 100.0 |
Immunochemistry | 2 | 0.0 |
Quinolines/*metabolism | 2 | 11.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 3 | 6.0 |
DNA, Complementary/biosynthesis | 4 | 7.0 |
Chromosome Mapping | 2 | 0.0 |
Epoxide Hydrolases/genetics/*metabolism | 2 | 40.0 |
Steroid Hydroxylases/metabolism | 3 | 4.0 |
Hamsters | 2 | 0.0 |
Arylamine N-Acetyltransferase/*genetics/metabolism | 2 | 3.0 |
United States/epidemiology | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/*metabolism | 3 | 17.0 |
Japan/epidemiology | 2 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Cytochrome P-450 CYP2E1 | 2 | 1.0 |
Aryl Hydrocarbon Hydroxylases/*antagonists & inhibitors/metabolism | 2 | 50.0 |
Predictive Value of Tests | 2 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Prospective Studies | 2 | 0.0 |
Coumarins/pharmacokinetics | 2 | 100.0 |
Risk | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*physiology | 2 | 33.0 |
Liver/*metabolism | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*antagonists & inhibitors/genetics | 2 | 50.0 |
Oxidoreductases, N-Demethylating/metabolism | 2 | 3.0 |
*Variation (Genetics) | 2 | 0.0 |
Sequence Analysis, DNA/methods | 2 | 2.0 |
